GSK-3β reactivation with LY294002 sensitizes hepatoma ells to chemotherapy-induced apoptosis

International Journal of Oncology

Volumn 27, Issue 1, 2005, Pages 215-222

  Beurel, Eléonore ^a   Kornprobst, Michel ^b   Blivet Van Eggelpoël, Marie José ^a   Cadoret, Axelle ^a   Capeau, Jacqueline ^a   Desbois Mouthon, Christele ^a  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Camptothecin; Death receptor; Etoposide; Mitochondria; Phosphatidylinositol 3 kinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CASP3 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; CASPASE; CASPASE 3; CASPASE 8; CHROMONE DERIVATIVE; CYTOCHROME C; DNA FRAGMENT; ENZYME INHIBITOR; ETOPOSIDE; FAS ANTIGEN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; SERINE; TNFRSF10A PROTEIN, HUMAN; TNFRSF10B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CHEMISTRY; ENZYME ACTIVATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; LIVER CELL CARCINOMA; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 8; CASPASES; CELL LINE, TUMOR; CHROMONES; CYTOCHROMES C; DNA FRAGMENTATION; ENZYME ACTIVATION; ENZYME INHIBITORS; ETOPOSIDE; FLOW CYTOMETRY; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MORPHOLINES; MUTATION; PHOSPHORYLATION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 24644485965     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Debatin KM and Krammer PH: Death receptors in chemotherapy and cancer. Oncogene 23: 2950-2966, 2004.
2. Brenner C, Le Bras M and Kroemer G: Insights into the mitochondrial signaling pathway: what lessons for chemotherapy? J Clin Immunol 23: 73-80, 2003.
3. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
4. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296:1655-1657,2002.
5. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554, 2004.
6. O'Gorman DM, McKenna SL, McGahon AJ, Knox KA and Cotter TG: Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia 14: 602-611, 2000.
7. Neri LM, Borgatti P, Tazzari PL, Bortul R, Cappellini A, Tabellini G, etat The phosphoinositide 3-kinase/AKTl pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res 1: 234-246, 2003.
8. Krystal GW, Sulanke G and Litz J: Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 1: 913-922, 2002.
9. Hu L, Hofmann J, Lu Y, Mills GB and Jaffe RB: Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087-1092,2002.
10. Clark AS, West K, Streicher S and Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1:707-717, 2002.
11. Brognard J, Clark AS, Ni Y and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997, 2001.
12. West KA, Sianna Castillo S and Dennis PA: Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Update 5: 234-248, 2002.
13. Cohen P and Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol 2: 769-776, 2001.
14. Jope RS and Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95-102, 2004.
15. Gotoh J, Obata M, Yoshie M, Kasai S and Ogawa K: Cyclin Dl over-expression correlates with beta-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis. Carcinogenesis 24: 435-442, 2003.
16. Desbois-Mouthon C, Blivet-Van Eggelpoel MJ, Beurel E, Boissan M, Delelo R, Cadoret A, et al: Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells. Hepatology 36: 1528-1536, 2002.
17. Ban KC, Singh H, Krishnan R and Seow HF: GSK-3beta phosphorylation and alteration of beta-catenin in hepatocellular carcinoma. Cancer Lett 199: 201-208, 2003.
18. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C, et al: Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 20: 252-259, 2001.
19. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, et al: Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO- l/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99: 403-413,1997.
20. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS and Dixit VM: An induced proximity model for caspase-8 activation. J Biol Chem 273: 2926-2930, 1998.
21. Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
22. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, et al: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7: 793-803, 2000.
23. Christian SL, Sims PV and Gold MR: The B cell antigen receptor regulates the transcriptional activator beta-catenin via protein kinase C-mediated inhibition of glycogen synthase kinase-3. J Immunol 169: 758-769, 2002.
24. Tsujio I, Tanaka T, Kudo T, Nishikawa T, Shinozaki K, Grundke-Iqbal I, et al: Inactivation of glycogen synthase kinase-3 by protein kinase C delta: implications for regulation of tau phosphorylation. FEBS Lett 469: 111-117, 2000.
25. Troussard AA, Tan C, Yoganathan TN and Dedhar S: Cellextracellular matrix interactions stimulate the AP-1 transcription factor in an integrin-linked kinase- and glycogen synthase kinase 3-dependent manner. Mol Cell Biol 19: 7420-7427, 1999.
26. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X and Jope RS: Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem 278: 48872-48879, 2003.
27. Bijur GN and Jope RS: Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport 14: 2415-2419,2003.
28. Watcharasit P, Bijur GN, Zmijewski JW, Song L, Zmijewska A, Chen X, et al: Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc Natl Acad Sci US A 99: 7951-7955, 2002.
29. Gibson SB, Oyer R, Spalding AC, Anderson SM and Johnson GL: Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 20: 205-212, 2000.
30. Nam SY, Jung GA, Hur GC, Chung HY, Kim WH, Seol DW, et al: Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 94: 1066-1073, 2003.
31. Panka DJ, Mano T, Suhara T, Walsh K and Mier JW: Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 276: 6893-6896, 2001.
32. Wang Q, Wang X, Hernandez A, Hellmich MR, Gatalica Z and Evers BM: Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem 277: 36602-36610, 2002.
33. Schwartz JD, Schwartz M, Mandeli J and Sung M: Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 3: 593-603, 2002.